{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tuberculosis/background-information/complications/","result":{"pageContext":{"chapter":{"id":"dc328fb0-65a2-5d6a-94fe-0bfa42962928","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field d3685f44-5588-4353-b832-ad6b5613ab0f --><h2>What are the complications?</h2><!-- end field d3685f44-5588-4353-b832-ad6b5613ab0f -->","summary":"","htmlStringContent":"<!-- begin item 34f94f08-36b6-420d-af19-1ba0682ade16 --><!-- begin field bde5029d-b2d5-418d-8809-395c3ecc8098 --><p><strong>Complications of tuberculosis (TB) include:</strong></p><ul><li>Reduced quality of life — a diagnosis of TB may be associated with fear, anxiety, social isolation, and stigma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>].</li><li>Transmission to others — if left untreated, a person with active pulmonary TB may infect 10–15 people every year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">PHE, 2015a</a>].</li><li>Drug resistance — worldwide in 2017, 558,000 people (range 483,000–639,000) developed TB resistant to rifampicin (the most effective first-line drug), and of these, 82% had multidrug-resistant TB. In 2015, 55% of people with multidrug-resistant TB or rifampicin-resistant TB worldwide successfully completed treatment (cured or treatment completed). For the remainder, 8% had treatment failure, 15% of people died, 14% were lost to follow-up, and 7% had no recorded outcome information [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">WHO, 2018b</a>].</li><li>Post-TB bronchiectasis, chronic obstructive pulmonary disease, and aspergillomas (occur in residual lung cavities) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Dheda, 2016</a>]. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/bronchiectasis/\">Bronchiectasis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/\">Chronic obstructive pulmonary disease</a> for more information.</li><li>Post-TB cor pulmonale/respiratory failure — this may result from lung cavitation, scarring, and fibrosis following pulmonary TB [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Dheda, 2016</a>].</li><li>Death — in 2016, 5.5% of people notified in England were reported to have died at the last recorded outcome, and TB is known to have caused or contributed to 35.2% of these deaths [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">PHE, 2018a</a>]. Globally, the absolute number of TB deaths among HIV-negative people has fallen by 5% since 2015, and by 20% among HIV-positive people, however, TB remains one of the top 10 causes of death and the leading cause from a single infectious agent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">WHO, 2018b</a>].</li></ul><!-- end field bde5029d-b2d5-418d-8809-395c3ecc8098 --><!-- end item 34f94f08-36b6-420d-af19-1ba0682ade16 -->","topic":{"id":"c8d06469-2b39-5daa-bda8-b076b7204860","topicId":"c1897d19-8ea9-40e5-84a7-c45a80747a3e","topicName":"Tuberculosis","slug":"tuberculosis","lastRevised":"Last revised in January 2019","chapters":[{"id":"7216c242-e6e9-5726-9bad-d4bbd4071072","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"aa25f749-53e8-5ff7-a3be-ddfd9f824295","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9c40ce5c-b940-5a6e-a414-cb379ae5f2c1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5b948ae0-2789-5df7-b344-42eb6ae4054d","slug":"changes","fullItemName":"Changes"},{"id":"706989f4-45e1-583c-bcbc-d08833e25634","slug":"update","fullItemName":"Update"}]},{"id":"5edbfe3e-e825-5d79-a1d2-fa1b3b258467","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2e115c8b-8ca5-587b-bf34-83ddeeae2383","slug":"goals","fullItemName":"Goals"},{"id":"dbbfc2a1-e777-55e9-b654-44db5bf1efb4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bdce292e-6c5f-53df-a014-fc8432efa249","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1f5efb77-1619-5cf3-be88-86fd03247324","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6f93c9e3-2eb5-5d68-bbc0-99b7ea53b835","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a028a0db-e900-5a0f-88ba-f333bcd824c9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"24cda0d7-3e0d-58d5-9229-0a15e99013c4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c26e051a-e3f8-57b8-95af-985e9e93a3aa","slug":"definition","fullItemName":"Definition"},{"id":"2deaf55e-4677-569a-a2e0-a8748b44829f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f2d695cb-4d0e-5513-a7f3-01df45726347","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"dc328fb0-65a2-5d6a-94fe-0bfa42962928","slug":"complications","fullItemName":"Complications"},{"id":"72382f51-4bac-5de9-9caf-c6f16082070d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7e56c88f-1492-52ab-9f0b-cfc6b986db85","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b5294e44-2490-5ba7-8d81-0085ae3114a7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b90838b4-5d6d-57e8-aabd-afaad5a60e3f","slug":"investigations","fullItemName":"Investigations"},{"id":"8d7ee3e2-c863-574f-a042-172b8d909e84","slug":"screening","fullItemName":"Screening"},{"id":"a6c65c83-026b-50f1-b32d-5d28e8e7ae46","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"880c8c31-e325-5d4b-b4de-6ac05a1a9f94","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ab22745-718a-5096-a75f-2e6c874d6267","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"fd726cd9-2566-5903-9e38-d7333b140c5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ac0b667-89b4-5934-98e1-938fd35e537f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3834823-1bb2-52a0-92c5-cb04316db808","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b2e2271f-aaf8-57a5-aba4-42de8a475bc5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e611555b-70b5-5ea6-8e53-5220621e1603","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fdb64832-ab19-58f6-978e-d73fe8657b7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"200b04d2-7d10-5430-abe3-3802b135aea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74113d46-a800-5f0b-9d3d-096dc4137936","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"24cda0d7-3e0d-58d5-9229-0a15e99013c4","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}